Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities

A Prospective, Multicenter, Randomized, Controlled Clinical Investigation of PalinGen® Flow Amniotic Tissue Allograft to Assess Safety, Tolerability, and Preliminary Efficacy for the Treatment of Chronic Lower Extremity Cutaneous Ulcers Compared to Standard of Care

The purpose of this study is to assess the safety and preliminary efficacy of PalinGen® Flow for the treatment of chronic ulcers of the lower legs and feet.

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Ulcer of Lower Extremity
• Intervention / Treatment: Biological: PalinGen Flow Amniotic Tissue Allograft

• Study Type: Interventional
• Enrollment (Actual): 82
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Sponsor Regulatory Affairs Manager; Phone Number: 888-232-8550; Email: quality@amniotechnology.com

Study Locations

• United States
  • California
    • Carmichael, California, United States, 95608
      • Center for Clinical Research
    • Castro Valley, California, United States, 94546
      • Center for Clinical Research
    • Fresno, California, United States, 93710
      • Limb Preservation Platform
    • San Francisco, California, United States, 94115
      • Center for Clinical Research
    • Vista, California, United States, 92083
      • ILD Research Center
  • Texas
    • Fort Worth, Texas, United States, 76104
      • Acclaim Bone & Joint Institute and Plastic Surgery
    • McAllen, Texas, United States, 78501
      • Futuro Clinical Trials

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Able to read, understand and sign the informed consent form (ICF)
• Available and willing to complete all study assessments
• At least 12 weeks post lower extremity revascularization procedure, if one has been performed

• Have chronic ulcer(s) of the lower extremities with the following characteristics:

  • Of diabetic or vascular etiology
  • Duration of ≥4 weeks, unresponsive to SOC
  • ≤20 cm2 in area
  • Extend through the full thickness of the skin but not down to muscle, tendon, or bone

• For subjects with VLU:

  • Ulcer area is ≥1.5 cm2 and ≤20 cm2 and with a clean, granulating base with minimal adherent slough
  • Ulcer location is at or above the ankle (malleolus) and below the knee
  • Ulcer location is appropriate for use of compression therapy treatment

• For subjects with DFU:

  • Ulcer area is ≥1.5 cm2 and ≤ 20 cm2 and is amenable to off-loading
  • Subject has diabetes mellitus (Type 1 or Type 2), requiring insulin or oral/injectable medications to control blood glucose levels
  • Glycosylated hemoglobin (HbA1c) level at screening is <12%
• Adequate circulation to the affected lower extremities
• Total serum bilirubin, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), hemoglobin, WBC, and PLT count all within limits specified in study protocol
• No renal impairment or mild renal impairment, defined as creatinine clearance ≥50 mL/min (by Cockroft-Gault estimation)
• Male subjects and female subjects of childbearing potential must use acceptable methods of contraception

Exclusion Criteria:

• Clinical evidence of ongoing infection and/or receipt of IV, oral, or topical antimicrobials at the Baseline Visit
• Wheelchair bound or bed-ridden (ambulatory with assistance is acceptable)
• Ulceration at the site of amputation
• Undergoing renal dialysis
• Known or suspected malignancy in the target ulcer, or a history of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancer)
• Documented history of osteomyelitis at the target ulcer location within 6 months of screening

• Current treatment or anticipated need for treatment over the course of the study with:

  • Immunosuppressants (including topical or systemic corticosteroids or glucocorticoids)
  • Cytotoxic chemotherapy
  • Growth hormone
  • Oral or systemic antifungal or antituberculosis treatment
• History of radiation at the ulcer site
• New York Heart Association Class III or IV congestive heart failure or uncontrolled cardiac dysrhythmia
• Diagnosis of autoimmune disease(s) (rheumatoid arthritis, lupus, psoriasis, Sjogren's syndrome) or arthritis requiring corticosteroid treatment
• Target ulcer(s) previously treated with negative pressure, hyperbaric oxygen, or tissue engineered materials (eg, Apligraf®, EpiFix® or Dermagraft®) or other scaffold materials (eg, Oasis, Matristem) within 4 weeks prior to Screening Visit
• Target ulcer(s) anticipated to require negative pressure wound therapy or hyperbaric oxygen at any time during the study

• Subjects with VLU who have:

  • Deep vein thrombosis diagnosed within 4 weeks prior to Screening Visit
  • Refusal or inability to tolerate compression therapy

• Subjects with DFU who have:

  • Active Charcot foot (stable chronic Charcot foot is not exclusionary)
  • Ulcers on toes 2, 3, 4, and/or 5 only (ulcer on plantar surface of the great toe only is not exclusionary)
• Pregnant or breast feeding
• Allergic to DMSO
• Healing of target ulcer is observed to be ≥35% at the end of the Run-in Period (between Screening and Baseline Visits)
• Presence of any condition(s) which compromises the subject's ability to complete this study, including subjects with a known history of poor adherence to medical treatment
• Subjects who, in the opinion of the Investigator, are not able to comply with study requirements
• Treatment with an investigational drug(s) or device(s) within the 4 weeks preceding Screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Standard of Care (SOC); Participants will receive SOC for chronic ulcers of the lower extremities.
Experimental: PalinGen Flow Treatment plus SOC; Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.	Biological: PalinGen Flow Amniotic Tissue Allograft; Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants in the PalinGen Flow plus SOC group versus SOC alone with treatment-emergent adverse events (TEAEs)	Treatment-emergent adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and graded per the CTCAE Version 5.0.	All adverse events (AEs) and serious adverse events (SAEs) will be recorded from the time of signing of the informed consent form through Week 64.
Proportion of participants in the PalinGen Flow plus SOC group versus SOC alone who achieve complete ulcer closure by Week 12.	Complete wound closure will be assessed by the Bates-Jensen Wound Assessment Tool (BWAT) and a photographic imaging and measurement device.	BWAT assessment and wound imaging will be performed at each study visit through end of treatment (Week 12)

Collaborators and Investigators

• Sponsor: Amnio Technology, LLC
• Investigators: Principal Investigator: Joseph M Caporusso, D.P.M., Futuro Clinical Trials

Study record dates

Study Major Dates

• Study Start (Actual): January 19, 2021
• Primary Completion (Estimated): March 1, 2024
• Study Completion (Estimated): January 31, 2025

Study Registration Dates

• First Submitted: December 8, 2020
• First Submitted That Met QC Criteria: December 11, 2020
• First Posted (Actual): December 14, 2020

Study Record Updates

• Last Update Posted (Actual): March 20, 2024
• Last Update Submitted That Met QC Criteria: March 18, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Diabetic ulcer; Venous stasis ulcer
• Additional Relevant MeSH Terms: Pathologic Processes; Skin Diseases; Skin Ulcer; Ulcer; Leg Ulcer
• Other Study ID Numbers: PGF-201

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No